3470 results for «2025年12月MSCI美国50和标普500配置策略»
3470 results
What are the essentials of the provisional strategy for non-left main true bifurcation lesions?
21 May 2025 – From EuroPCR 2025
Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
How to implement the diagnosis of INOCA in everyday practice?
20 May 2025 – From EuroPCR 2025
In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these...
In what situation is emergency transcatheter valve intervention a valid alternative to surgery?
16 Nov 2025 – From PCR London Valves 2025
Azeem Latib and Giuseppe Tarantini discuss how transcatheter therapies are increasingly used to treat critically ill patients with severe valvular disease and cardiogenic shock—patients once considered untreatable. They highlight cases ranging from severe AS with ACS to acute papillary muscle rupture and acute severe regurgitation, showing...
From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS
16 Nov 2025 – From PCR London Valves 2025
Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...
From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system
16 Nov 2025 – From PCR London Valves 2025
Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...
TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR
12 Feb 2026 – From PCR London Valves 2025
Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation.
ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...
How to successfully approach calcified bifurcation lesions?
20 May 2025 – From EuroPCR 2025
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario.
In this discussion, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explain why this subset deserves dedicated attention. They highlight the critical role of intra-coronary imaging to...
How to successfully approach CTO interventions: a step-by-step approach
22 Oct 2025 – From EuroPCR 2025
Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.
The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
One-year results from the ADALA trial
16 Nov 2025 – From PCR London Valves 2025
Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.
The study compared three months of low-dose DOAC with three months of...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
Early treatment of severe aortic stenosis: do we need to wait?
20 May 2025 – From EuroPCR 2025
Rahul Sharma and Darren Walters share their perspectives on shifting treatment strategies for aortic stenosis (AS), with a focus on early intervention.
Their conversation draws on the EARLY TAVR trial, which compared transcatheter aortic valve replacement (TAVR) to clinical surveillance in patients with severe, asymptomatic AS at low surgical...
Five-year outcomes following early experience with transapical TMVR
16 Nov 2025 – From PCR London Valves 2025
In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.
The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no...
Digital late breakers: will LAAC become standard practice for patients with AF?
12 Mar 2026
Register for free to this webinar on 15 April at 5:00pm (UTC+2) with P. Garot, M. Bergmann and J.E. Nielsen-Kudsk and review current indications for LAAC, and so much more!
TAVI Durability: Evidence and contemporary practice
20 Mar 2026
Register for free to this webinar on Monday 13 April at 5:00pm with O. Demir, T. Nestelberger and T. Rheude and review the contemporary evidence on TAVI durability, and much more!
Discover all about the Best personalised vascular care project Award
EuroPCR 2026: Promotional kit
PCR Rio Valves 2026: Promotional kit
